Dossier
eGFR
Coverage of eGFR in the Nexus archive.
- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
Otsuka's Voyxact slowed kidney function loss in IgA nephropathy patients by 3 points annually versus 7.6 points with placebo in a Phase 3 trial, but the effect was less than expected. The drug's performance left room for competing treatments to outperform.